Business Wire

Patient Safety Movement Foundation Calls for Action in Advance of Second Annual #UniteForSafeCare Event

Share

The second annual #UniteForSafeCare event is scheduled for Friday, September 17th in conjunction with World Patient Safety Day. The event is hosted by the Patient Safety Movement Foundation (PSMF) and co-convened with The Leapfrog Group to bring global awareness to the lack of safety in healthcare and the fact that more than three million people die each year as the result of unsafe care. The event will explore how the public and other stakeholders can call for high reliability in healthcare, as well as the World Health Organization’s 2021 theme of “safe maternal and newborn care.”

As part of this year’s event, leadership from the Patient Safety Movement Foundation will coordinate demonstrations on both the east and west coasts in honor of World Patient Safety Day. Patient Safety Movement Foundation CEO Dr. David B. Mayer will continue his walk which began in February 2020 to raise awareness of patient and healthcare worker safety. Since starting, he has covered over 3,400 miles and been joined by families impacted by patient harm in over 30 states. This year’s walk will begin on September 11th on the 20th anniversary of the terrorist attacks to honor the lives lost and impacted, and will start in Gettysburg, Penn. Gettysburg was chosen as the starting point due to its strong visual representation of lives lost during the American Civil War drawing parallel to the lives lost each day due to unsafe care. The walk will finish in front of the White House in a call for action before continuing on to Capitol Hill.

“Over 8,220 people die every day in hospitals worldwide from unsafe care that’s six people every minute and the pandemic is making the delivery of safe care even harder,” stated Mayer. “This annual event allows us to bring the community and stakeholders together to raise awareness of this issue and advocate for change to make zero preventable deaths a reality.”

Here are the ways you can get involved this year:

  • Attend the free virtual event: The virtual event will occur from 11 a.m. to 3:15 p.m. PDT on Friday, September 17th. At the event, attendees will have the chance to hear from Patient Safety Movement Foundation leadership, as well as over 20 speakers including Tedros Adhanom Ghebreyesus, PhD, MSc, director-general of the World Health Organization. Dariush Eghbali, an Iranian artist and humanitarian, will be performing and attendees will have the opportunity to network and access exhibitor booths. In addition, there will be a panel with the showrunner and cast of Peacock’s TV series “Dr. Death” followed by a segment to memorialize the patients we’ve lost due to preventable harm. Attendees will have the opportunity to bid on items up for auction – including a private screening and Q&A session with the filmmaker of HBO’s “Bleed Out,” as well as a conversation with Patrick Macmanus, the showrunner of “Dr. Death.” All proceeds of the auction support awareness and education initiatives. To see the full schedule and RSVP, visit: https://patient.sm/B15-UFSC.
  • Host your own walk: Download the Charity Miles app and walk on your own or invite your coworkers and community to dedicate a walk, run, bike or any movement to show your support for the cause.
  • Make a donation : Donations help fund awareness and education campaigns throughout the year. Individuals can make donations in honor of loved ones who have been affected by preventable medical harm. PSMF will plant an orange flag in Orange County or Washington D.C. for any donation of $10 or more. To help PSMF reach its goal of $250,000, visit: https://patient.sm/PR-UFSC-Donate.
  • Share on social: Spread the word and help advocate for safer care by increasing awareness on social media. Use the hashtag #uniteforsafecare or translate it into any language to keep the conversation going globally.
  • Send in your art: New this year, a virtual patient, family and survivor art gallery is available for individuals to share personal expressions of the emotions they felt as they navigated experiences with medical errors – whether it ended in tragedy or in joy. The art will be displayed along with a place to share the meaning behind the piece. To view the art or submit your own piece, visit: https://patient.sm/B15-Artwork.
  • Wear and “light up” orange: Show your support by wearing orange, the official World Patient Safety Day color, or lighting up your house, a local monument or business orange. Share your photos on social media between September 13th and September 17th. You can also purchase official campaign t-shirts and hats: https://patient.sm/B15-Shop.

This year’s event is made possible by the generous sponsorship of Dr. Steven J. Barker, Gordon & Betty Moore Foundation, HealthySimulation.com, Jewish Healthcare Foundation, Josie King Foundation, Kaiser Permanente, Liamar Healthcare, Medstar Health Institute for Quality and Safety and Teletracking. To learn more about #UniteForSafeCare, visit: https://patientsafetymovement.org/unite-for-safe-care/home/.

About the Patient Safety Movement Foundation: Each year, more than 200,000 people die in U.S. hospitals and more than three million globally as a result of unsafe care. The Patient Safety Movement Foundation (PSMF) is a global non-profit with a vision to eliminate preventable patient harm and death across the globe by 2030. PSMF unites patients, advocates, healthcare providers, medical technology companies, government, employers and private payers in support of this cause. From its Actionable Patient Safety Solutions and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org, and follow PSMF on LinkedIn, Twitter, Instagram and Facebook.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Leslie Licano, Beyond Fifteen Communications, Inc.
psmf@beyondfifteen.com | (949) 733-8679 ext.101

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 10:05:00 EET | Press release

TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver

RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge ® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 10:00:00 EET | Press release

Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support commercial manufacturing of Omisirge® for this additional indication at its state-of-the-art cGMP cell therapy manufacturing facility in Hopkinton, MA. “We are excited to expand our collaboration with RoslinCT to add US manufacturing as Omisirge® moves into its next phase with the recent FDA approval for patients suffering from severe apl

Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 08:00:00 EET | Press release

Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It proves a supplier has undergone an exhaustive audit of its governance, security controls, and operational processes. For Dutch financial institutions, this qualificatio

Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 04:00:00 EET | Press release

Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f

Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 03:00:00 EET | Press release

Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye